On Wednesday, UK-based biopharmaceutical company Amryt Pharma, which develops innovative treatments for rare diseases, made its U.S. debut on the Nasdaq, trading as AMYT.
This isn't the company's first foray into the stock market, but CEO Joe Wiley says the expansion to the U.S. should help the company grow its business further.
"We are already listed in London, so we are now dual-listed in both the U.S. and the UK," Wiley said. "We also hope to enhance our value of our equity on both sides of the Atlantic through this dual-listing. Thirdly, we believe this enhances our credibility as a biotech company and our access to deal globally as we continue our strategy to acquire, develop, and commercialize."
One other factor contributing to Amryt Pharma's decision to go public in U.S. markets was due to where the company's shareholders are located. Roughly 70 percent of the company's shareholders are already located in North America and the company hopes to expand its reach there.
"We believe that this IPO will increase the awareness of Amryt in the U.S. by increasing our Amyrt coverage." Wiley then added, "We believe that we can access a deeper pool of capital and healthcare investors in the U.S. This will ultimately drive liquidity in our shares, which is what our goal is."
Although not in the race to develop a COVID-19 vaccine, by focusing on rare and orphan diseases, the company believes its future is bright. As an example, Wiley pointed to his company's study of epidermolysis bullosa, a group of rare and genetic disorders of the skin, as one reason investors should remain interested.
"Analysts who cover this area believe that north of a $1 billion market opportunity...We actually did the world's largest-ever study in EB...we will read our data from that in late Q3 or early Q4 this year."
The stunning indictment that led to the arrest of more than 30 people — including Miami Heat guard Terry Rozier and other NBA figures — has drawn new scrutiny of the booming business of sports betting in the U.S. The multibillion-dollar industry has made it easy for sports fans — and even some players — to wager on everything from the outcome of games to that of a single play with just a few taps of a cellphone. But regulating the rapidly-growing industry has proven to be a challenge. Professional sports leagues’ own role in promoting gambling has also raised eyebrows.
Tesla, the car company run by Elon Musk, reported Wednesday that it sold more vehicles in the past three months after boycotts hit hard earlier this year, but profits still fell sharply. Third-quarter earnings fell to $1.4 billion, from $2.2 billion a year earlier. Excluding charges, per share profit of 50 cents came in below analysts' estimate. Tesla shares fell 3.5% in after-hours trading. Musk said the company's robotaxi service, which is available in Austin, Texas, and San Francisco, will roll out to as many as 10 other metro areas by the end of the year.
Starbucks’ AI barista aims to speed service and improve experience. Nick Lichtenberg, Fortune Business Editor, explains its impact on workers and customers.
As Big Tech reports Q3 earnings, investors await proof that massive AI and cloud investments from Meta, Apple, Microsoft, and Alphabet are driving real growth.
Eric Trump joins us to discuss American Bitcoin’s mission, market strategy, and why he believes the U.S. must lead the next era of digital currency innovation.
Unreal Snacks CEO Kevin McCarthy shares how dye-free candy is leading the sweets revolution—just in time for what could be a record-breaking Halloween 2025.
